Investor Relations Captor Therapeutics ®
Information on research and development progress in the CT-02 project
Current Report No. 56/2023
Date of preparation: 6 December 2023.
Subject: Information on research and development progress in the CT-02 project.
Legal basis: Article 17 (1) MAR - confidential information.
The Management Board of Captor Therapeutics S.A., with its registered office in Wroclaw (the "Company"), informs about progress in the project CT-02, dedicated to the development of therapies for autoimmune and inflammatory diseases based on targeted protein degradation.
In recent weeks, the company has developed molecules that are potent NEK7 degraders with diverse chemotypes: a systemic chemotype and a chemotype capable of crossing the blood-brain barrier. It has been demonstrated that NEK7 degraders under in vitro conditions allow for the inhibition of the activation of the NLRP3 inflammasome pathway, indicating their anti-inflammatory potential. This opens up broad therapeutic areas for the use of systemic NEK7 degraders in autoimmune and inflammatory diseases, including gout, inflammatory bowel disease, dermatological pathologies, and many others. NEK7 degraders penetrating the brain however, could find applications in treating diseases of the central nervous system (CNS), where neuroinflammation occurs, such as Parkinson's disease, Multiple Sclerosis, or Amyotrophic Lateral Sclerosis.
The indicated therapeutic possibilities are confirmed by these key results , where strong and prolonged, almost complete degradation of the NEK7 protein in Macaca fascicularis monkeys was demonstrated for both the systemic and brain penetrant groups of degraders after oral administration.
As result of these data, the Company plans to separate the pipeline of the CT-02 project into two independent projects: the development of NEK7 degraders for the treatment of systemic diseases and the development of NEK7 degraders for the treatment of CNS-related diseases.
In the next stage, the Company will enter into discussions focused on the commercialization of the CT-02 project. Due to the intended separation of the CT-02 project into two independent projects, the Company will actively consider the possibility of separate commercialization of each project, which could be more financially beneficial for the Company. At the same time, the Company maintains its previous assumption that it will not incur further significant development expenses in connection with these separated projects, including during the course of discussions regarding their commercialization.
In the opinion of the Company's Management Board, the above information represents significant research and development progress on the CT-02 project and was therefore considered inside information.